Company news
Aptevo Therapeutics Inc. news in 2025
Aptevo Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
December 26, 2025
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
December 9, 2025
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
November 10, 2025
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
November 6, 2025
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
October 8, 2025
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
September 16, 2025
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
September 4, 2025
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
August 13, 2025
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
August 11, 2025
Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
June 19, 2025
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules
June 18, 2025
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML
June 18, 2025
Aptevo Participating in the BIO International Convention
June 13, 2025
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan
May 22, 2025
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig
May 15, 2025
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
May 8, 2025
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 22, 2025
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 21, 2025
Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
April 4, 2025
Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
April 3, 2025
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
March 20, 2025
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
March 18, 2025
Aptevo to Participate in March Conferences
March 6, 2025
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
February 13, 2025
Decks in 2025
- Investor Presentation (March 2025)
Investor deck · 27 slides · Mar 20, 2025
- Investor Presentation (February 2025)
Investor deck · 30 slides · Feb 11, 2025